Everolimus for the treatment of advanced renal cell carcinoma (Q37862261)

24 August 2017

1 reference

title

Everolimus for the treatment of advanced renal cell carcinoma (English)

1 reference

24 August 2017

Robert Amato

1

1 reference

PubMed ID

21470068

24 August 2017

language of work or name

English

0 references

publication date

7 April 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

7

1 reference

24 August 2017

1143-1155

1 reference

24 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Recent progress in the management of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

The role of hypoxia-induced factors in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

The activation of phosphatidylinositol 3-kinase by Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

The protein kinase B/Akt signalling pathway in human malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Renal-cell carcinoma--molecular pathways and therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Targeting von Hippel-Lindau pathway in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.571382

10.1517/14656566.2011.571382

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21470068